Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27163797 | 0.93 | NOTUM (0.45) | NOTUMCYP19A1KEAP1KCNH2GPR119 | |
| SCHEMBL27163355 | 0.83 | NOTUM (0.47) | NOTUMCYP19A1KEAP1KCNH2GPR119 | |
| SCHEMBL30046185 | 0.83 | NOTUM (0.47) | NOTUMCYP19A1KEAP1KCNH2GPR119 | |
| SCHEMBL21753379 | 0.77 | NOTUM (0.51) | NOTUMBRS3 | |
| SCHEMBL20300553 | 0.75 | NOTUM (0.63) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL1163413 | 0.74 | NOTUM (0.61) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL20409464 | 0.74 | NOTUM (0.61) | NOTUMCYP19A1KEAP1KCNH2GPR119 | |
| SCHEMBL1188176 | 0.74 | NOTUM (0.52) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL10447781 | 0.73 | NOTUM (0.78) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL27163150 | 0.72 | CHRM1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | NOTUM 3162/4885CYP19A1 783/4885KEAP1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.